Legal Actions Surge Against Soleno Therapeutics Over DCCR Safety Allegations

Legal Actions Intensify Against Soleno Therapeutics Following DCCR Concerns

Soleno Therapeutics, Inc. faces a class action lawsuit initiated on behalf of investors who acquired the company's shares between March 26, 2025, and November 4, 2025. This legal challenge emerges in the aftermath of Soleno's disappointing announcement regarding its treatment for hyperphagia associated with Prader-Willi Syndrome, known as DCCR (VYKAT™ XR). Following this revelation, which raised significant safety issues, Soleno's stock price plummets by 26%. The law firm Hagens Berman leads the charge, investigating possible violations of federal securities laws due to Soleno's alleged misleading public statements regarding the safety and efficacy of DCCR.

The crux of the lawsuit revolves around claims that Soleno underreported serious safety concerns concerning fluid retention, which became increasingly apparent during Phase 3 clinical trials. Investors argue that the company's assurances regarding the drug's launch and commercial viability contradicted emerging evidence bringing to light heightened risks, including potential heart failure incidents in children. Activist short-seller Scorpion Capital first brought these safety issues to public attention in August 2025, highlighting distressing cases linked to DCCR and prompting skepticism about Soleno's previously optimistic statements.

As litigation progresses, the allegations suggest an unsettling pattern of communication from Soleno, raising fears about the drug's market viability and the potential withdrawal from the market. With a lead plaintiff deadline set for May 5, 2026, affected investors are encouraged to report their losses and engage with legal representatives to explore their rights and potential recovery options.

In addition to the lawsuit from Hagens Berman, other law firms, including the Schall Law Firm and DJS Law Group, also announce similar legal actions against Soleno for purported violations of the Securities Exchange Act of 1934. These firms focus on helping investors reclaim losses incurred due to misleading communications about the safety profile of DCCR. They highlight the significance of taking prompt action, as participation in these class actions is contingent upon class certification.

The unfolding legal challenges underscore deepening concerns within the investment community about Soleno Therapeutics' drug candidate and the transparency of its corporate communications. With potential ramifications for both the company's future and its stakeholders, the situation reinforces the necessity of diligent oversight in the biotech industry—where the stakes are particularly high for vulnerable patient populations.